Skip to main content
SpringerLink
Log in

The Effects of Clozapine on Negative Symptoms in Patients with Schizophrenia with Minimal Positive Symptoms

  • Published:
Annals of Clinical Psychiatry

Abstract

The effectiveness of clozapine in the treatment of the negative symptoms of schizophrenia remains controversial, as improvements in negative symptoms are invariably accompanied by improvements in positive symptoms and neurological side effects. We examined the effectiveness of treatment with clozapine on negative symptoms in a cohort of patients with minimal positive symptoms. Improvements in positive and negative symptoms were measured by BPRS ratings in a subgroup of schizophrenic patients (n=17, from a state hospital cohort of 75) with minimal positive symptoms, who had received clozapine for 6 months. In this subgroup, significant improvements were noted by a composite score on the three negative symptom items of emotional withdrawal, blunted affect, and motor retardation. Positive and depressive symptoms remained unchanged. The remaining cohort (n=58) showed improvements in overall psychopathology including positive, negative, and depressive symptoms. Interestingly, nearly 50% of each group were discharged from the hospital. These findings suggest that clozapine may be beneficial in the treatment of core negative symptoms, even in the absence of other improvements in psychopathology. This effect of clozapine may be a function of its unique pharmacological profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17:263–287

    Google Scholar 

  2. Huttunen M: The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995; 15(Suppl):4S–10S

    Google Scholar 

  3. Baldessarini RJ, Frankenburg FR: Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324:746–754

    Google Scholar 

  4. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17:247–261

    Google Scholar 

  5. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287–302

    Google Scholar 

  6. Carpenter WT: The negative symptom challenge. Arch Gen Psychiatry 1992; 49:236–237

    Google Scholar 

  7. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effects of 6 months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41:892–897

    Google Scholar 

  8. Carpenter WT, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia. Am J Psychiatry 1988; 145:578–583

    Google Scholar 

  9. Pogue-Geile MF, Harrow M: Negative symptoms in schizophrenia: Their longitudinal course and prognostic importance. Schizophr Bull 1985; 11:427–439

    Google Scholar 

  10. Simpson GM, Varga E: Clozapine—A new antipsychotic agent. Curr Ther Res 1974; 16:679–686

    Google Scholar 

  11. Ekblom B, Haggstrom JE: Clozapine (Leponex) compared with chlorpromazine: A double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 1974; 16:945–957

    Google Scholar 

  12. Gerlach J, Koppelhus P, Helweg E, Monrad A: Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiat Scand 1974; 50:410–424

    Google Scholar 

  13. Singer K, Law SK: A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J Int Med 1974; 2:433–435

    Google Scholar 

  14. Chiu E, Burrows G, Stevenson J: Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust N Z J Psychiatry 1976; 10:343–347

    Google Scholar 

  15. Fischer-Cornelssen KA, Ferner UJ: An example of European multicenter trials: Multispectral analysis of clozapine. Psychopharmacol Bull 1976; 12:34–39

    Google Scholar 

  16. Guirguis E, Voineskos G, Gary J, Schlieman E: Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr Therapy Res 1977; 21:707–719

    Google Scholar 

  17. Gelenberg AJ, Doller JC: Clozapine versus chlorpromazine for the treatment of schizophrenia: Preliminary results from a double-blind study. J Clin Psychiatry 1979; 40:238–240

    Google Scholar 

  18. Shopsin B, Klein H, Aaronsom M, Collora M: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind comparison. Arch Gen Psychiatry 1979; 36:657–664

    Google Scholar 

  19. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377–384

    Google Scholar 

  20. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozaril collaborative study group: Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796

    Google Scholar 

  21. Leppig M, Bosch B, Naber D, Hippius H: Clozapine in the treatment of 121 out-patients. Psychopharmacology 1989; 99(Suppl):S77–S79

    Google Scholar 

  22. Mattes JA: Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years. J Clin Psychiatry 1989; 50:389–391

    Google Scholar 

  23. Meltzer HY, Bastani B, Young-Kwon K, Ramirez LF, Burnett S, Sharp J: A prospective study of clozapine in treatment resistant schizophrenic patients. Psychopharmacology 1989; 99(Suppl):S68–S72

    Google Scholar 

  24. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez L, Rapaport MH: Clinical and biological response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 1992; 49:345–353

    Google Scholar 

  25. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149:68–72

    Google Scholar 

  26. Clozapine Study Group: The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 1993; 163:150–154

    Google Scholar 

  27. Kuoppasalmi K, Rimon R, Naukkarinen H, Lang S, Sandqvist A, Leinonen E: The use of clozapine in treatment-refractory schizophrenia. Schizophr Res 1993; 10:29–32

    Google Scholar 

  28. Breier A, Buchanan RW, Irish D, Carpenter WT Jr: Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44:1145–1149

    Google Scholar 

  29. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20–26

    Google Scholar 

  30. Conley R, Gounaris C, Tamminga C: Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35:746

    Google Scholar 

  31. Lindenmayer JP, Grochowski S, Mabugat L: Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14:201–204

    Google Scholar 

  32. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comp Psychiatry 1994; 35:8–15

    Google Scholar 

  33. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744–1752

    Google Scholar 

  34. Jalenques I, Coudert AJ: Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients. Encephale 1994; 20:767–775

    Google Scholar 

  35. Overall JE, Gorham DR: “The brief psychiatric rating scale.” Psychol Rep 1962; 10:799–812

    Google Scholar 

  36. Andreasen NC: Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39:784–788

    Google Scholar 

  37. Andreasen NC: The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984

    Google Scholar 

  38. Asberg M, Schalling D: Construction of a new psychiatric rating instrument, the comprehensive psychopathological rating scale (CPRS). Prog Neuro-Psychopharmacol 1979; 3:405–412

    Google Scholar 

  39. Kay SR, Fizbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 2:261–276

    Google Scholar 

  40. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: Another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827–832

    Google Scholar 

  41. Meltzer HY: Clozapine: Is another view valid? Am J Psychiatry 1995; 152:821–825

    Google Scholar 

  42. Rao ML, Moller HJ: Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 1994; 30:160–172

    Google Scholar 

  43. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C: Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6:70–87

    Google Scholar 

  44. Kane JM, Safferman AZ, Pollack S, John C, Szymanski S, Kronig M, Lieberman JA: Clozapine, negative symptoms and extrapyramidal side-effects. J Clin Psychiatry 1994; 55(Suppl):74–77

    Google Scholar 

  45. Schwartz JT, Brotman AW: A clinical guide to antipsychotic drugs. Drugs 1992; 44:981–992

    Google Scholar 

  46. Singh MM, Kay SR: A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Psychopharmacologia 1975; 43:103–113

    Google Scholar 

  47. Roubicek J, Major I: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatry 1977; 12:613–633

    Google Scholar 

  48. Ranjan R, Meltzer HY: Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40:253–258

    Google Scholar 

  49. Weinberger DR, Aloia MS, Goldberg TE, Berman KF: The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci 1994; 6:419–427

    Google Scholar 

  50. Moghaddam B: Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance. J Clin Psychiatry 1994; 55(Suppl B):27–29

    Google Scholar 

  51. Ereshefsky L, Tran-Johnson TK, Watanabe MD: Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clin Pharmacy 1990; 9:682–707

    Google Scholar 

  52. Meltzer HY, Gudelsky GA: Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittel-Forschung 1992; 42:268–272

    Google Scholar 

  53. Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA: Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. Psychopharmacology 1993; 112(Suppl):S40–S54

    Google Scholar 

  54. Lingjaerde O: New perspectives on biological treatment of schizophrenia. Acta Psychiat Scand, 1994; 384(Suppl):102–107

    Google Scholar 

  55. Carpenter WT Jr, Conley RR: Therapeutic approaches to negative symptoms. In: Greden JF, Tandon R, eds. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC, American Psychiatric Press; 1991

    Google Scholar 

  56. Carpenter WT Jr, Heinrichs DW, Wagman AMI: Deficit and non-deficit forms of schizophrenia: The concept. Am J Psychiatry, 1988; 145:578–583

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

    Jaspreet S. Brar, K. N. Roy Chengappa, Haranath Parepally, Suzanne B. Kreinbrook & Rohan Ganguli

  2. Mayview State Hospital, Bridgeville, Pennsylvania

    K. N. Roy Chengappa, Haranath Parepally, Alan R. Sandman, Suzanne B. Kreinbrook & Sapna A. Sheth

Authors
  1. Jaspreet S. Brar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. N. Roy Chengappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haranath Parepally
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan R. Sandman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suzanne B. Kreinbrook
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sapna A. Sheth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rohan Ganguli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brar, J.S., Roy Chengappa, K.N., Parepally, H. et al. The Effects of Clozapine on Negative Symptoms in Patients with Schizophrenia with Minimal Positive Symptoms. Ann Clin Psychiatry 9, 227–234 (1997). https://doi.org/10.1023/A:1022352326334

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022352326334

Search

Navigation